IndexIQ Advisors’s Royalty Pharma RPRX Stock Holding History

IndexIQ Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2K	Buy	+55	New	+$2.16K	﹤0.01%	1288

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IndexIQ Advisors's RPRX Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Royalty Pharma (RPRX) in Q1 2022: 55 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1288 among its holdings.

279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

IndexIQ Advisors held 55 shares of Royalty Pharma worth $2K as of Q1 2022.
Royalty Pharma was a new IndexIQ Advisors position in Q1 2022.
Royalty Pharma made up ﹤0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #1288 holding.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.